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Kaiso, a p120 catenin-binding protein, is expressed in
the cytoplasmic and nuclear compartments of cells;
however, the biological consequences and clinical im-
plications of a shift between these compartments
have yet to be established. Herein, we report an en-
richment of nuclear Kaiso expression in cells of pri-
mary and metastatic prostate tumors relative to the
normal prostate epithelium. Nuclear expression of
Kaiso correlates with Gleason score (P < 0.001) and
tumor grade (P < 0.001). There is higher nuclear
expression of Kaiso in primary tumor/normal
matched samples and in primary tumors from Afri-
can American men (P < 0.0001). We further found
that epidermal growth factor (EGF) receptor up-regu-
lates Kaiso at the RNA and protein levels in prostate
cancer cell lines, but more interestingly causes a shift
of cytoplasmic Kaiso to the nucleus that is reversed by
the EGF receptor–specific kinase inhibitor, PD153035.
In both DU-145 and PC-3 prostate cancer cell lines,
Kaiso inhibition (short hairpin RNA-Kaiso) decreased
cell migration and invasion even in the presence of
EGF. Further, Kaiso directly binds to the E-cadherin
promoter, and inhibition of Kaiso in PC-3 cells results
in increased E-cadherin expression, as well as re-es-
tablishment of cell–cell contacts. In addition, Kaiso-
depleted cells show more epithelial morphology and
a reversal of the mesenchymal markers N-cadherin
and fibronectin. Our findings establish a defined on-
cogenic role of Kaiso in promoting the progression of
1836prostate cancer. (Am J Pathol 2012, 181:1836–1846; http://
dx.doi.org/10.1016/j.ajpath.2012.08.008)
Prostate cancer is the most commonly diagnosed malig-
nancy in men, with African American men experiencing a
rate 60% higher than white patients. At the time of diag-
nosis, approximately 50% of men have clinically ad-
vanced disease.1 The molecular mechanisms associated
with tumor development are the result of genetic and
epigenetic changes that promote tumor cell growth. DNA
methylation, the most common epigenetic change, re-
sults from changes in cytosine methylation, typically at
cytosine-guanine dinucleotides (CpG), or from changes
in DNA-associated proteins. Recently, it was proposed
that methylation alone is insufficient to silence transcrip-
tion2 and that recognition of methylated DNA by two
classes of proteins, those with a methyl-CpG binding
domain and those with C2H2 zinc fingers, such as Kaiso,
are required for transcriptional inactivation. Methyl-CpG
binding proteins recognize 5-methylcytosine and act as
intermediates between the transcriptional machinery and
methylated DNA. Of the methyl-binding proteins, Kaiso
has a 10-fold higher affinity and represses transcription in
part by recruiting the N-CoR corepressor.3
Kaiso, first identified as a p120 catenin (ctn)-binding
protein,4 is a member of the broad complex, tramtrak,
bric-a-brac/pox virus, and zinc finger superfamily. Struc-
turally, Kaiso contains a carboxyl-terminal region with
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clusters of methylated CpG dinucleotides as well as se-
quence-specific Kaiso binding sites.4 Several lines of
evidence from both in vitro and in vivo models suggest a
number of tumor suppressor genes, frequently silenced
by hypermethylation, such as HIC1, MTA2, E-cadherin
(CDH1), and matrilysin (MMP7) have been linked to Kaiso
transcriptional regulation.5,6 A clinical role for Kaiso also
has been proposed. Immunohistochemical analysis in
various tissue types shows that Kaiso is expressed in
both the cytoplasmic and/or nuclear compartments.
Studies in lung cancer show that Kaiso expression cor-
relates with clinicopathologic characteristics of malignant
tumors. However, functional studies using Kaiso antibody
or the shRNA-–depletion strategy resulted in enhanced
proliferation and invasiveness.6 Surprisingly, an opposite
role for Kaiso was implicated in colorectal studies, in
which down-regulation of Kaiso expression resulted in
decreased proliferation and an overall antitumor effect.2
Because Kaiso expression has been determined in mul-
tiple tumor types, additional studies are required to pro-
vide a detailed description of Kaiso expression and func-
tion in individual epithelial tumors.
Growth factors such as epidermal growth factor (EGF)
have been well established to promote cell motility, inva-
sion, and metastasis in multiple tumors. This promotes
genetic and epigenetic changes that lead to a down-
regulation of E-cadherin, via receptor tyrosine kinase sig-
naling, and/or promoter hypermethylation. As a result,
epithelial cells undergo an epithelial-to-mesenchymal
transition, in which cells are directed to assume a less-
differentiated phenotype with the acquired ability for me-
tastasis. Previously, we showed that E-cadherin can be
re-expressed through direct pharmacologic abrogation
of EGF receptor (EGFR) signaling7 or within the meta-
static tumor microenvironment,8 resulting in less invasive
and more cohesive cells. However, whether Kaiso has a
functional role and specific involvement in EGFR-associ-
ated epithelial-to-mesenchymal transition has not been
explored. Herein, we show that Kaiso is highly expressed
in primary prostate tumors and lymph node metastases,
with significant increases for African Americans com-
pared with white patients in high-grade tumors. Further-
more, a cytoplasmic-to-nuclear shift occurs in tumors and
this correlates with increasing tumor grade and Gleason
score. We further identified that EGF induces nuclear
localization of Kaiso, which subsequently is associated
with an increase in cell migration and invasion and sup-
pression of tumor suppressor E-cadherin expression.
These results show that Kaiso functions in an oncogenic
manner, in which aberrant localization in the nucleus is
essential for prostate cells to acquire the ability to metas-
tasize.
Materials and Methods
Cell Culture, Antibodies, and Reagents
Human prostate cancer cell lines LNCaP, DU-145, and
PC-3 were obtained from the ATCC and routinely werecultured in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum (Gibco, Paisley,
Scotland) and antibiotics in a humidified atmosphere of
5% CO2 in air. In these conditions the duplication period
of the cells is 36 hours.
DU-145 EGFR-overexpressing cells [wild type (WT)
DU-145] were generated by transfecting DU-145 cells
with retroviral-containing EGFR constructs.7 Primary an-
tibodies were obtained as follows: Kaiso 6F clone (Ab-
cam, Boston, MA); anti-Kaiso clone 6F (Upstate Biotech-
nology, Billerica, MA); anti-Kaiso 12H (Santa Cruz, CA);
p120ctn, E-cadherin, and N-cadherin (BD Biosciences,
OR). Mouse secondary antibodies, Alexa 488, 594, and
625, were obtained from Invitrogen (OR). Human EGF
was obtained from BD Biosciences (KY). The EGFR-spe-
cific tyrosine kinase inhibitor, PD153035, was purchased
from CalBiochem (CA). Other reagents were obtained
from Sigma-Aldrich (St. Louis, MO).
Immunohistochemistry
The prostate cancer tissue microarrays were obtained
from US Biomax (Rockville, MD) or from the Anatomical
Pathology Division at the University of Alabama at Bir-
mingham. The use of tissue was approved by the Insti-
tutional Review Board of both Tuskegee University and
the University of Alabama at Birmingham. Immunohisto-
chemistry was performed using the anti-Kaiso clone 6F
(Upstate Biotechnology) and 12H clone (Santa Cruz)
as previously described. Duplicate microarrays were
stained for evaluation by immunohistochemistry.8 Briefly,
cells were blindly scored by two pathologists with similar
results. Individual specimens were scored separately for
membranous, cytoplasmic, and nuclear staining for
Kaiso and classified with respect to the intensity of im-
munostaining, with the percentage of cells determined at
each staining intensity from 0 to 4.9 To permit numeric
analysis, the proportion of cells at each intensity can be
multiplied by that intensity. Statistical analyses were per-
formed using the Pearson 2 test to analyze the relation-
ships between cytoplasmic and nuclear expression of
Kaiso and clinicopathologic factors.
Immunoblotting
Cells were grown to 80% confluency in six-well plates.
Lysates were prepared from cultured cells in a solution
containing 50 mmol/L Tris, pH 7.5; 120 mmol/L NaCl;
0.5% Nonidet p-40; 40 mol/L phenylmethylsulfonyl flu-
oride; 50 g/mL leupeptin; and 50 g/mL aprotinin (all
from Sigma-Aldrich). Cells were allowed to lyse for 1 hour
on ice. The lysed cells were centrifuged, and the resulting
supernatants were extracted and quantitated by use of a
Bradford assay. Lysates (30 g of protein) were sepa-
rated by 8% SDS PAGE, immunoblotted, and analyzed
by chemiluminescence (Amersham Biosciences, NJ).
Densitometry was performed using NIH ImageJ software
version 1.46 (Bethesda, MD).
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Subcellular fractionation of cells was performed as pre-
viously described.10 Cytosolic and nuclear fractions, and
the DU-145, DU-145 WT, and PC-3 cells were resus-
pended in a hypotonic buffer [10 mmol/L Tris (pH 7.5),
1.5 mmol/L MgCl2, 10 mmol/L KCl, 1 mmol/L dithiothrei-
tol, pepstatin, leupeptin] and homogenized using a glass
douncer. The cells were centrifuged at 13,000  g and
the supernatant was collected (cytosolic fraction). The
nuclei were resuspended in a high-salt buffer [20 mmol/L
HEPES (pH 7.9), 25% glycerol, MgCl2, 1.2 mol/L KCl, 0.2
mmol/L EDTA, 0.2 mmol/L phenylmethylsulfonyl fluoride,
1 mmol/L dithiothreitol] and rotated at 4°C. Lysates then
were separated by 7.5% SDS PAGE, immunoblotted, and
analyzed by chemiluminescence (Amersham Biosci-
ences).
Immunofluorescence Microscopy
Cells (3  105) were grown to 80% confluency on glass
coverslips. Cells then were fixed with methanol alone or
4% paraformaldehyde, permeabilized with 100 mmol/L
Tris-HCl (pH 7.4), 150 mmol/L NaCl, 10 mmol/L EGTA,
1% Triton X-100, 1 mmol/L phenylmethylsulfonyl fluoride,
and 50 g/mL aprotinin (all from Sigma-Aldrich) and sub-
sequently blocked with 5% bovine serum albumin for 1
hour at room temperature. Identical results were obtained
with both methods. Samples were incubated with indi-
cated primary antibodies diluted in blocking buffer at 4°C
overnight. Fluorescein isothiocyanate–conjugated sec-
ondary antibody (BD Biosciences) was added. Cells then
were treated with DAPI for nuclear staining and analyzed
with a disk scanning unit confocal microscope (Olympus,
Pittsburgh, PA). To determine the relative intensities, the
total area of cytoplasmic and nuclear regions of each
image was measured as well as the threshold intensity for
each channel using Metamorph Imaging Software ver-
sion 7.5 (Molecular Devices, Inc, Sunnyvale, CA). Differ-
ences between intensities then were determined by Excel
(Microsoft, Redmond, WA). Bar graphs represent n  3
images sectioned and individually analyzed for total area.
All quantitative data were normalized to appropriate con-
trol images.
Quantitative RT-PCR
RNA was extracted from prostate cancer cells using
TRIzol (Invitrogen). cDNA was prepared using Super-
script III First Strand cDNA Synthesis kits (Invitrogen) and
detected by Kaiso-specific TaqMan (Invitrogen). The
housekeeping gene hypoxanthine-guanine phosphoribo-
syltransferase (HRPT1; Applied Biosystems, Carlsbad,
CA) was used as an endogenous control for all RNA
samples. RNA analyses were performed in triplicate, and
fold change was calculated using the Ct value
method.RNA Interference
To generate stable short hairpin RNA (shRNA) Kaiso
cells, the HuSH 29-mer for Kaiso was provided in the
pRFP-C-RS plasmid driven by the U6-RNA promoter.
Plasmid DNA pRFP-C-RS, containing puromycin-resis-
tant gene, expressing Kaiso-specific shRNA, and scram-
bled shRNA were transfected into DU-145 or PC-3 cells
using Lipofectamine 2000 (Invitrogen). The medium was
replaced by T medium containing 2 g/mL puromycin for
selection of antibiotic-resistant colonies over a period of 3
weeks. The puromycin-resistant cells were further se-
lected by use of red fluorescence protein as a marker to
enrich for cells expressing shRNA. sh-Kaiso cells were
plated at clonal densities, and more than 20 clones were
chosen to determine the degree of knockdown. Clones
with the lowest Kaiso levels were retained for further
analysis.
Cell Migration
Migration of cells was assessed by their ability to move
into an acellular area; this was accomplished with a
two-dimensional wound-healing assay, as previously
described.11 With cells at 70% to 80% confluence, a
denuded area was generated in the middle of each
well with a rubber policeman. The cells then were ex-
posed to EGF (0 or 10 ng/mL) and incubated for 24
hours in dialyzed media. The rate of migration was
determined and quantified in Metamorph Imaging Soft-
ware. All measurements were normalized to values for
controls.
Invasion Assay
Cell invasiveness was determined by the capacity of cells
to migrate across a layer of extracellular matrix, matrigel,
in a Boyden chamber. Briefly, 20,000 cells were plated in
the matrigel-containing chamber in serum-free medium
containing 1% bovine serum albumin for 24 hours; this
then was replaced with a serum-free medium for an ad-
ditional 24 hours. The number of cells that invaded
through the matrix over a 48 hour-period was determined
by counting cells that stained with crystal violet on the
bottom of the filter. All experiments were performed in
triplicate.
Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation experiments were per-
formed with the use of the ChIP-IT Kit (Active Motif, Carls-
bad, CA). In brief, PC3 cells were fixed in 1% formalde-
hyde at room temperature for 10 minutes; the fixation
reaction was stopped by adding a 1:10 volume of 10
glycine to the tube at room temperature for 5 minutes.
The cell pellets were resuspended and incubated for 30
minutes in ice-cold lysis buffer with phenylmethylsulfonyl
fluoride and proteinase inhibitor cocktail. The nuclear
pellets were resuspended in shearing buffer, and chro-
matin was sheared to an average size of 200 to 1500 bp
by sonication at 25% power for 10 pulses of 20 seconds
and lym
Nuclear Kaiso in Prostate Cancer 1839
AJP November 2012, Vol. 181, No. 5each, with a 30-second rest on ice between each pulse.
Chromatin (10 L) was saved for input DNA control.
Sheared chromatin was incubated in chromatin immuno-
precipitation buffer with 25 L of protein G magnetic
beads and anti-Kaiso antibody (Abcam), mouse RNA
Polymerase II (Active Motif), and rabbit IgG antibody
(Active Motif) as a negative control on a rolling shaker at
4°C for 4 hours. The immunoprecipitated chromatin was
purified from the chromatin-antibody mixture by several
washing steps, and the chromatin-immunoprecipitated
DNA was eluted in 50 L of elution buffer AM2 (Active
Motif). Cross-links were reversed by adding 50 L of
reverse cross-link buffer. After removing proteins by
digestion with proteinase K, the purified DNA was used
as templates for PCR analysis. The primers used were
designed to amplify a 422-bp methylated fragment
of the E-cadherin promoter (1163 to 1585): 5=-
AGGAGGCTGATAGAGGAGAACC-3= and 5=-GATTGA-
GACCATCCTGGCTAAC-3=.
Statistical Analysis
For all experiments, statistics were performed with Mi-
crosoft Excel or Prism software version 5.0 (GraphPad,
La Jolla, CA). An independent Student’s t-test was used
to determine statistical differences between experimental
and control values. Median scores were obtained from a
subset of patients to statistically evaluate Kaiso expres-
sion. Tissue correlations were performed with Matlab
(Mathworks, Inc, Natick, MI). P values 0.05 were con-
Figure 1. Abnormal nuclear expression of Kaiso in prostate cancer specim
specimens are shown. A: Kaiso levels in a normal, healthy prostate with low
adjacent PCa tumors showed discernible cytoplasmic staining in epithelia,
hyperplasia showed cytoplasmic positivity with low nuclear positivity. D:
expression with cytoplasmic and nuclear positivity. E and F: High grade 4
Original magnification: 400.sidered statistically significant.Results
Kaiso Expression and Subcellular Localization
To evaluate the expression and localization of Kaiso dur-
ing prostate cancer progression, immunohistochemistry
was used to evaluate samples from 172 patients, consist-
ing of normal tissue (9 patients), benign prostatic hyper-
plasia (14 patients), adjacent normal tissue (17 patients),
primary tumors (142 patients), and metastases (4 pa-
tients). There was low expression of the Kaiso protein in
luminal cells of noncancerous samples (Figure 1A); ex-
pression was predominantly in the membrane or cyto-
plasm (Figure 1, B and C). There was, however, nuclear
expression of Kaiso in the basal cells of adjacent normal
tissue (Figure 1B). Scoring for nuclear Kaiso staining
intensities 0 to 4 (as mentioned in Materials and Methods)
between normal, low Gleason, and high Gleason are
summarized in Table 1.
In contrast to previous reports, Kaiso expression was
observed within the nucleus, with weak to moderate ex-
resentative data from immunohistochemical studies of 172 prostate cancer
g seen in glandular epithelia. B: Kaiso expression in normal epithelia from
clear positivity in the basal cells. C: Kaiso expression in benign prostatic
pression in low grade 1 tumors showed a general up-regulation of Kaiso
ph node metastasis showed uniform intense nuclear expression of Kaiso.
Table 1. Nuclear Kaiso Expression in Normal, Low Gleason,
High Gleason, and Lymph Node Metastases Prostate
Carcinomas
Kaiso
Normal
(n  26)*
Low
Gleason
(n  52)
High
Gleason
(n  50) Mets
No score (0) 9
Weak (0–1) 10 18 4
Moderate (2–3) 7* 28 10
Strong (3–4) 6 36 4ens. Rep
stainin
and nu
Kaiso ex*Adjacent normal.
P value
et.
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and strong intense expression in tumors with high Glea-
son scores and in metastases (Figure 1, E and F). To
determine the clinical significance of subcellular localiza-
tion of Kaiso expression, we performed 2 analysis. Me-
dian values of scoring intensities were used to separate
the low and high tumor grades and Gleason scores.
Nuclear expression of Kaiso was found to correlate sig-
nificantly with tumor grade of 2 (P  0.001) and Glea-
son score of 7 (P  0.001) (Table 2). Cytoplasmic
expression was observed in tumor samples; however,
correlations with clinicopathologic features were not
found to be significant. Increased nuclear expression
occurred in a stage-specific manner, with the largest
differential expression between metastatic tumors and
normal samples; however, differences between primary
tumors and normal samples were significant as well (Fig-
ure 2A). Further characterization of nuclear Kaiso expres-
sion in high grade tumors of similar-age African American
men (n  22) and white (n  18) primary tumors showed
that African American patients expressed higher mean
values of Kaiso (P  0.0001) independent of grade and
age (Figure 2B). Further Kaiso nuclear expression signif-
icantly correlated with race (P  0.0032) (see Supple-
mental Table S1 at http://ajp.amjpathol.org).
To determine whether there is a shift in Kaiso localiza-
tion in prostate tumors, matched normal and tumor sam-
ples were evaluated (n  13). Cytoplasmic expression
was decreased significantly in paired primary tumors
compared with normal samples (P 0.0001) (Figure 2C);
however, there were significant increases in nuclear ex-
pression within the same patients (P  0.0001) (Figure
2D). This analysis supports the idea that there is a pro-
gressive enhancement of abnormal Kaiso expression
during prostate cancer progression and that the extent of
abnormal expression correlates with progression.
Expression and Subcellular Localization of Kaiso
in Prostate Cancer Cell Lines
Because there have been no reports of Kaiso expression
Table 2. Correlation of Kaiso Subcellular Localization with Clinic
Characteristics All patients
Cytoplasmic Ka
expression
0.53 (median)
Total 142 70
Age
69.5 (median) 71 27
69.5 71 43
Grade
2 70 39
2 69 29
Gleason score
7 52 20
7 50 17
PSA, ng/mL 15 4
17, median 15 5
*P value for the correlation of the mean expression with clinical feature.
without clinical information. Median scores were obtained for each subsin prostate cancer cell lines, its expression and localiza-tion were evaluated in LNCaP, DU-145, and PC-3 cells,
and in a DU-145 subline (DU-145WT) that was genetically
engineered to overexpress EGFR. DU-145 WT cells es-
cape EGFR down-regulation and show enhanced inva-
siveness in vitro13 and in vivo.14 Quantitative RT-PCR
showed that Kaiso levels were increased at the mRNA in
DU-145 WT and PC-3 cells compared with LNCaP and
DU-145 cells (see Supplemental Figure S1A at http://
ajp.amjpathol.org). Confocal images show that Kaiso is
located in both the cytoplasmic and nuclear compart-
ments in all cell lines. However, the more aggressive
ures
P*
Nuclear Kaiso
expression
P*2.45 (median) 2.45
73 69
0.0072 35 36 0.6145
38 33
0.1066 57 13 0.001
13 56
0.6394 29 23 0.001
10 40
0.1587 3 12 0.058
8 7
s were obtained with the 2 test. Statistics were not performed on samples
Figure 2. Quantitative analysis of nuclear Kaiso in prostate tumor progres-
sion. A: Nuclear expression of Kaiso was analyzed and presented in a box
plot. Nuclear Kaiso levels increase monotonically from normal, benign pros-
tatic hyperplasia (BPH), adjacent normal, primary tumor, and metastasis,
with all four P values less than 0.05. (P  0.016, normal and BPH; P  0.01,
BPH and adjacent normal; P  0.0001, adjacent normal and malignant; and
P  0.0001, malignant and metastasis). B: Points represent nuclear Kaiso
staining intensity of individual African American and white patients of similar
age (ages, 67 to 80) and grade 3; bars represent the median value for the
sample set. *P 0.0001. Cytoplasmic Kaiso expression (C) and nuclear Kaisoal Feat
iso
0.53
72
44
28
31
40
32
33
11
10expression (D) in paired (surrounding nontumor) normal and primary tumor
tissues from n  13 prostate cancer patients. *P  0.0001.
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of nuclear expression compared with LNCaP and DU-
145 cells (see Supplemental Figure S1B at http://ajp.
amjpathol.org), which was verified after quantification of
fluorescent intensity in each compartment (see Supple-
mental Figure S1C at http://ajp.amjpathol.org). The influ-
ence of EGFR expression on Kaiso localization was
shown further by the fact that subcellular fractions of
DU-145 WT cells show increased nuclear expression,
whereas DU-145 cells show low amounts of nuclear lev-
els, which correlated with the confocal images (see Sup-
plemental Figure S1D at http://ajp.amjpathol.org). Thus, it
appears that the subcellular localization of Kaiso is asso-
ciated with EGFR expression.
Activation of EGFR Signaling Results in
Increased Kaiso Expression and Nuclear
Localization
Various lines of evidence suggest the involvement of
EGFR signaling in prostate cancer.15,16 To identify EGFR
as an upstream regulator of Kaiso, 10 ng/mL EGF, a
concentration showing the most significant fold increase
Figure 3. EGF induces Kaiso expression and cytoplasmic-to-nuclear localization in
treatedwith 10 ng/mL of EGF for 0, 1, 6, and 24 hours and assayed formRNAKaiso l
phosphoribosyltransferase (HPRT1) as the loading control. Data are normalized to c
using anti-Kaiso antibody and anti–-actin antibody as loading control. Images sh
individual time intervals and comparedwith control.C:Kaiso subcellular localization
(green)with nuclear stain DAPI (blue) after EGF treatment in DU-145 cells. Images sh
quantification of Kaiso intensity in the individual cytoplasmic and nuclear compartm
is the mean  SD of three individual experiments. Data are normalized to 0 hours
presence or absence of 10 ng/mL EGF or EGFR-specific kinase inhibitor, PD153035,
control. Data were normalized to control; n 4 SE. *P 0.05. F: Kaiso protein l
absence of 10 ng/mL EGF or EGFR-specific kinase inhibitor, PD153035, in DU-145WT and PC
individual experiments. h, hours.(data not shown), was used in a time-dependent assay
over 24 hours. DU-145, DU-145 WT, and PC-3 lines
showed incremental increases in Kaiso expression at the
RNA level; DU145WT cells showed the greatest increase
(fourfold) as early as 1 hour after EGF stimulation (Figure
3A). Increases in Kaiso expression also were observed at
the protein level, as determined by immunoblots, with
significant increases observed as early as 6 hours and
sustained over 24 hours of exposure to EGF (Figure 3B).
Because we observed that increases in Kaiso expres-
sion are associated with a subcellular localization pattern
in our patient cohort, we further determined if EGFR-
induced increases in Kaiso expression coincided with a
subcellular localization in our cell culture model. After
only 0.5 hours, EGF caused perinuclear accumulation of
previously dispersed Kaiso in DU-145 cells, with visible
nuclear accumulation at 1 hour. After 24 hours, significant
increases in both cytoplasmic and nuclear expression
were observed, although nuclear expression was the
most significant (Figure 3, C and D). DU-145WT and PC-3
cells, which endogenously express high levels of nuclear
Kaiso, showed similar trends as DU-145 cells. Both cy-
toplasmic and nuclear Kaiso expression increased on
cancer cell lines. A:DU-145, DU-145 WT, and PC-3 prostate cancer cell lines were
uantitative RT-PCRwith Kaiso-specific TaqMan primers and hypoxanthine-guanine
 4 SE (*P 0.05). B: Kaiso protein levels in whole-cell lysates by immunoblot
representative of three individual experiments. Densitometry was performed on
as determined by immunofluorescence. Note the colocalization of Kaiso in nucleus
representative of three individual experiments. Scale bars: 25mol/L.D:Bar-graph
U-145 cells treated with 10 ng/mL of EGF compared with untreated control; shown
*P  0.05. E: Kaiso mRNA levels were determined by quantitative RT-PCR, in the
5WT and PC-3 cells using Kaiso-specific TaqMan primers andHPRT1 as the loading
re determined by immunoblot in the cytoplasm and the nucleus in the presence orprostate
evels by q
ontrol; n
own are
(green)w
own are
ents of D
control.
in DU-14
evels we-3 cells.-actin served as loading control. Images shown are representative of three
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significantly higher throughout the exposure time periods
(see Supplemental Figure S2, A and B, at http://ajp.
amjpathol.org). To more clearly define the role of EGFR
activation on increases in Kaiso expression and loca-
lization, we used an EGFR-specific kinase inhibitor,
PD153035 (500 nmol/L), in the presence or absence of
EGF. PD153035 significantly reduced mRNA Kaiso ex-
pression levels even after EGF pretreatment (Figure 3E).
After subcellular fractionation and subsequent immuno-
blot of both DU-145 WT and PC-3 cells, we also observed
that PD153035 significantly reduced expression of Kaiso
in the cytoplasmic and nuclear compartments (Figure 3F;
see also Supplemental Figure S2C at http://ajp.amjpathol.
org), which is a reversal of the expression pattern ob-
served in endogenously expressing and EGF-treated
DU-145 WT and PC-3 cells. Thus, EGFR signaling posi-
tively affects Kaiso expression and subcellular locali-
zation.
Promotion by Kaiso of EGFR-Induced Prostate
Cancer Cell Migration and Invasion
To further define the function of Kaiso in prostate can-
cer cells, DU-145 and PC-3 cells were stably trans-
duced with a plasmid vector containing the sh-Kaiso
silencing sequence (Figure 4A). Both sh-Kaiso DU-145
and sh-Kaiso PC-3 clones showed delayed migration,
even in the presence of EGF stimulation, as measured
by wound-healing assays (Figure 4, B and C). These
results show that Kaiso is a mediator of EGFR-induced
migration of prostate cancer cells. For cancer cells to
invade surrounding tissue, the cells must degrade the
underlying basement membrane. To determine the
function of Kaiso in invasion by prostate cancer cells,
sh-Kaiso PC-3 and sh-DU-145 were seeded onto a
filter coated with Matrigel and compared with cells
exposed to the vector only. Suppression of endoge-
nous Kaiso expression resulted in inhibition of cell in-
vasion, resulting in a reduction in the ability of the cells
to invade through Matrigel (Figure 4D).
Repression of E-Cadherin by Kaiso in Prostate
Cancer Cells
In various cancer types, increased cell migration and
invasion has been attributed to growth factor–induced
loss of E-cadherin or to hypermethylation of the E-cad-
herin promoter.17,18 Because Kaiso has high affinity for
methylated dinucleotide sequences and is regulated by
EGFR (Figure 3A), we next sought to determine whether
suppression of Kaiso restored E-cadherin expression in
sh-Kaiso PC-3 cells. Control PC-3 cells and vector-only
cells showed no E-cadherin expression, as previously
reported.18 sh-Kaiso PC-3 cells, however, show eightfold
increased expression of E-cadherin mRNA, as measured
by quantitative RT-PCR. Furthermore, the level of re-ex-
pression was comparable with that of PC-3 cells exposed
to the demethylating agent 5-aza-2=-deoxycytidine (Fig-Figure 4. Kaiso is required for EGF-induced cell migration and invasion. A:
shRNA Kaiso down-regulated Kaiso levels at mRNA as determined by quantita-
tive RT-PCR with Kaiso-specific TaqMan primers and HPRT1 as the loading
control or protein levels by immunoblot. B: -actin served as loading control,
shRNA DU-145 or PC-3 cells were wounded and treated with EGF for 24 hours.
Vertical bars indicate the starting area migration on day 0. Photographs were
taken at100 magnification and DU-145 images serve as representative images
of both DU-145 and PC-3 cell lines. C: Quantification of area migrated in the
presence or absence of EGF stimulation in shRNA DU-145 or PC-3 cells com-
pared with scrambled control si-Scr show that Kaiso depletion significantly
decreased cell migration. Data were normalized to control (gray bar). D: shRNA
DU-145 and PC-3 cells were plated on Matrigel-coated filters and the invasive
cells were fixed, stainedwith crystal violet, and counted. shRNAKaiso cells show
decreased invasiveness compared with sh-Scr and controls. All data presented
are the mean of three independent experiments  SE. *P  0.05.
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E-cadherin and p120ctn expression, and a decrease in
mesenchymal markers N-cadherin and fibronectin ex-
pression at the protein level, as determined by immuno-
blots (Figure 5B). To determine whether Kaiso directly
binds to E-cadherin, we performed a chromatin immuno-precipitation assay. Immunoprecipitated DNA was incu-
bated with anti-Kaiso antibody, anti-RNA pol II (positive
control), or IgG antibody (negative control), and sub-
jected to PCR with specific primers designed to amplify
the Kaiso (mCGmCG) binding sites in the E-cadherin
promoter region. Our results showed that the Kaiso anti-
body (not negative control IgG antibody) enriched a
mCGmCG fragment within the E-cadherin promoter (Fig-
ure 5C). These results show that Kaiso can bind directly
to methylated regions in the E-cadherin promoter in PC-3
cells.
It is well recognized that membrane expression of E-
cadherin regulates cell polarity and increases cell–cell
cohesiveness, limiting the migratory ability of tumor
cells.10,19 Therefore, we performed immunofluorescence
for E-cadherin and p120ctn in sh-Kaiso PC-3 cells com-
pared with vector only sh-Scr PC-3 cells. sh-Kaiso cells
showed E-cadherin at cell–cell contacts as well as in-
creased p120ctn, which is rate limiting for E-cadherin
stability,20,21 at the cellular membrane (Figure 5D). Fur-
thermore, sh-Kaiso PC-3 cells also showed more of an
epithelial morphology compared with the mesenchymal
morphology shown by sh-Scr PC-3 cells (Figure 5C).
Collectively, these results suggest that EGFR-regulated
expression and subcellular re-localization of Kaiso pro-
motes methylation-related gene silencing of E-cadherin.
Discussion
Kaiso previously was observed to be localized predom-
inately in the cytoplasm of various tumor types, including
prostate cancer.22 Herein, we observed positive nuclear
expression of Kaiso in aggressive tumors from prostate
cancer patients. This expression profile was reproduc-
ible, using two commercially available antibodies to both
the 6F8 and 12H epitopes. Semiquantitative analysis of
Kaiso expression shows that nuclear expression signifi-
cantly correlates with increasing tumor grade and Glea-
son score. A correlation with nuclear expression and PSA
levels also was observed, although it was not found to be
significant, possibly owing to the limited number of pa-
tients with documented PSA information. Although a large
number of patients showed nuclear positivity, we indeed
Figure 5. Kaiso regulates E-cadherin expression. A: E-cadherin mRNA levels
were determined by quantitative RT-PCR in sh-Kaiso PC-3 cells, sh-Scr (vec-
tor only), and control cell treated with demethylating agent, 5-aza-2=-deoxy-
cytidine (5-aza) using E-cadherin TaqMan-specific primer with HPRT1 as the
loading control. Data were normalized to control (n  4)  SE B: sh-Kaiso
PC-3 cells, sh-Scr (vector only), and control lysates were immunoblotted with
an anti–E-cadherin, anti–N-cadherin antibody, antifibronectin antibody, and
anti-p120ctn antibody. -actin served as loading control. Shown is one of two
representative blot series. C: Chromatin sample from PC-3 cells was sub-
jected to chromatin immunoprecipitation by mouse IgG (lane 1) and specific
antibodies against RNA pol II (lane 2) and Kaiso (6F/6F8, ChIP grade, lane 3).
Mouse IgG was used as a negative control. Lane 4 was no DNA negative
control. Chromatin immunoprecipitation products were analyzed by real-
time PCR specific E-cadherin primer set (1290 to 1570) to amplify the
methylated region. D: E-cadherin and p120ctn localization was determined
by immunofluorescence in sh-Kaiso or sh-Scr PC-3 cells using anti–E-cad-
herin (red) and DAPI nuclear stain (blue). Arrows indicate E-cadherin
staining at cell–cell junctions. Differential interference contrast (DIC) images
show an altered cellular morphology in sh-Kaiso PC-3 compared with sh-Scr
PC-3 cells (bar, 25 mol/L).
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hort. Low levels of expression were observed in the cy-
toplasm in normal and benign patients. Critical analysis
of a subpopulation of normal/tumor paired samples from
13 individual patients showed that although Kaiso ex-
pression was cytoplasmic in normal tissues, the corre-
sponding malignant samples showed a shift to the nu-
clear compartment. Furthermore, colorectal tumors from
theMuc2/ in vivomouse model also showed significant
increases in Kaiso expression, as well as positive nuclear
expression compared with normal matched control.23
These findings further emphasize a role for nuclear Kaiso
in tumorigenesis.
Various cell types have displayed subcellular localiza-
tion of Kaiso in culture. A report by Soubry et al22 showed
that micronenvironmental differences, such as two-di-
mensional versus three-dimensional Matrigel culture con-
ditions or cell density, influences both subcellular local-
ization and expression. Dense three-dimensional cultures
of nontumorigenic MCF-10A cells over a multiday period,
showed a cytoplasmic re-localization and eventual loss of
Kaiso expression as cultures become dense, which also
is associated with E-cadherin present at the membrane.
HT29 or SW48 colon cancer cells, which display nuclear
Kaiso, did not show a difference in Kaiso localization,
even under hypoxic conditions. However, no single factor
has been associated with localization of Kaiso in the
cytoplasmic and nuclear compartments to date.22,24,25
EGF, abundantly secreted in the primary tumor microen-
vironment,26,27 is up-regulated during hypoxia,28 and is a
robust promoter of cell migration, invasion, and metasta-
sis.14,29 Commonly used DU-145 and PC-3 cells, and a
DU-145 WT cell line, in which we overexpress EGFR,14,30
reveal that the more aggressive DU-145 WT and PC-3
cells show increased Kaiso expression and nuclear lo-
calization, whereas LNCaP and DU-145 cells show lower
levels and an increased ratio of cytoplasmic-to-nuclear
Kaiso. Furthermore, this is independent of culture den-
sity. This would suggest that Kaiso subcellular localiza-
tion, at least in part, is influenced by Kaiso levels within
the cell. There are two lines of evidence in support of this
hypothesis. First, we observed that EGF stimulation re-
sults in an increased expression and a cytoplasmic-to-
nuclear expression shift in DU-145 cells. However, in the
reverse experiment in DU-145 WT and PC-3 cells, block-
ing EGFR signaling resulted in a decrease in overall
Kaiso levels in both the cytoplasmic and nuclear com-
partments. Second, Madin-Darby canine kidney epithe-
lial cells and MCF-7 breast cancer cells, which both dis-
play Kaiso predominately in the cytoplasm, display
immediate nuclear expression after overexpression with
Kaiso cDNA in both cell lines.31 The fact that activation or
attenuation of EGFR signaling, as opposed to cell density
alone, modulated Kaiso expression and localization is
likely owing to reinforced autocrine signaling in the highly
aggressive carcinoma cell lines compared with noncar-
cinoma and/or early stage carcinoma cell lines, which do
not possess this feature. Although we did not determine
whether Kaiso is phosphorylated in response to EGF, it
appears that Kaiso is similar to other cancer-related tran-
scription factors (ERK and ZEB1) that normally reside inthe cytoplasm until they are signaled to translocate to the
nucleus. These findings establish that expression and
subcellular localization of Kaiso is at least partially influ-
enced by EGFR.
We have found in prostate carcinoma lines that inhibi-
tion of the autocrine EGFR loop (and likely the EGFR-
induced hepatocyte growth factor/c-met autocrine
loop32), either by direct disruption of the signaling loop or
by secondary site signaling trans-attenuation, results in
E-cadherin re-expression and a re-localization of both
p120ctn and E-cadherin to cell–cell contacts.18,33,34 E-
cadherin expression is down-regulated by two mecha-
nisms: posttranslational modification35 or hypermethyl-
ation of promoter.36 In addition to E-cadherin, the
proposed Kaiso target gene SA100A4 (mts-1) typically is
silenced by methylation in epithelial tumors,5,37 and has
been implicated in EGFR-mediated cell migration as
well.18,38,39 Our results showed that shRNA-targeted de-
pletion of Kaiso in both DU-145 and PC-3 cells showed
decreased cell migration and invasion, even in the pres-
ence of EGF stimulation. Furthermore, sh-Kaiso PC-3
cells, which have a partially methylated E-cadherin pro-
moter,40 re-express E-cadherin at RNA and protein levels
similar to those caused by exposure to the demethylating
agent 5-aza-2=-deoxycytidine. Similar to findings in
NIH3T3 cells,5 we did observe that Kaiso directly binds to
CpG-rich regions in the E-cadherin promoter. As a result
of E-cadherin re-expression, sh-Kaiso cells also dis-
played morphologic changes, which coincided with de-
creases in the mesenchymal markers N-cadherin and
fibronectin. Together these markers are of clinical impor-
tance in determining epithelial versus mesenchymal cells
in various tumor types including prostate cancer.41 We
did not observe any changes in S100A4 or MMP expres-
sion in this model (data not shown), although both have
been implicated in EGFR signaling. This is surprising,
given that both SA100A4 and MMP-7 have been linked to
Kaiso through methylation or consensus sequence bind-
ing.12,37 However, collectively, our findings suggest that
Kaiso is a promoter of cell migration through loss of
cell–cell cohesiveness.
These observations provide a plausible explanation for
a number of events during the progression to aggressive-
ness in epithelial tumors. For example, E-cadherin pro-
moter is hypermethylated in most early stage lobular
breast tumors; however, expression of E-cadherin protein
is retained. It is only in late-stage tumors, which coincide
with our observed nuclear Kaiso shift, that a lack of E-
cadherin protein expression coincides with promoter hy-
permethylation.42 More specifically, immunohistochemi-
cal staining displayed loss of p120ctn and E-cadherin
expression at the leading edge of squamous cell carci-
nomas, which coincides with nuclear Kaiso positivity.22
Although a Kaiso-p120ctn complex has been observed in
the nucleus of other cell types,15,24,43 similar to squa-
mous cell carcinomas, nuclear p120ctn has not been
observed in prostate tumors.44,45 We did not observe
nuclear p120ctn in any of the prostate cancer cell lines,
even after EGF treatment (data not shown). Thus, the
p120ctn–Kaiso relationship in the nucleus, at least in
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siveness.
The observation that Kaiso was increased in African
American patients was intriguing. Several reports have
shown that EGFR is overexpressed in African American
prostate cancer patients.46 In addition, SOS1, which is a
regulator of EGFR expression and downstream signaling,
also is increased in African American prostate cancer
patients as well.47 Because our findings show that Kaiso
expression is positivity-influenced by EGFR activation, it
is possible that overexpression of EGFR contributes to
increased Kaiso levels in this patient population. Al-
though this currently remains speculative, it does begin
to provide more insight into why African American pros-
tate cancer patients show more aggressive disease pro-
gression than do white patients in epidemiologic stud-
ies.48,49 More work should be performed to further define
this relationship, specifically in African American prostate
cancer patients.
In summary, Kaiso cytoplasmic-to-nuclear localization
correlates with many features of prostate cancer progres-
sion, including race. Epithelial-to-mesenchymal transition
has been identified as a common mechanism underlying
therapeutic resistance and has been linked to poor prog-
nosis in many types of cancer, including prostate can-
cer.50 The fact that we found that Kaiso is regulated
through EGFR activity provides additional mechanistic
insight into the signaling pathway that apparently contrib-
utes to aggressive prostate cancer. Because a large
number of tumor/metastasis suppressor genes are si-
lenced as a result of methylation, Kaiso could be a central
regulator of many key events that contribute to tumori-
genesis and aggressiveness. Targeting of growth factor
receptors has shown minimal therapeutic effects for pros-
tate cancers. Nevertheless, targeting of downstream me-
diators of metastasis, such as Kaiso, could be a rational
approach for developing a new target for directed ther-
apies.
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